Prospective primary human lung cancer tumoroids to predict treatment response

Recruiting

Conditions: Lung cancer
tumour material
10038666

Registration Number: NL-OMON54034

Lead Sponsor: MAASTRO clinic

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 600

Inclusion Criteria

• All patients selected to undergo primary surgical resection of a primary lung
cancer. All types of resection are eligible, e.g. wedge resection, segmental
resection, lobectomy, pneumonectomy.
• All patients with (suspected) lung cancer that will undergo a bronchoscopy or
endobronchial ultrasound guided transbronchial needle aspiration
(EBUS/EUS-TBNA) bronchoscopy.

Exclusion Criteria

- Incompetent
- <18 years of age

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To establish matched normal and primary human lung cancer tumoroids from<br /><br>patient-derived (tumor) tissue material</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. To define oncogenic drivers in lung cancer tumoroids<br /><br>2. To investigate the stability of (epi-) genetic and phenotypic tumor<br /><br>heterogeneity of cultured tumoroids compared to a primary/secondary biopsy.<br /><br>3. To predict sensitivity and to get insight in the molecular biology of the<br /><br>response to immunotherapy, radiotherapy, cytotoxic and targeted agents.<br /><br>4. To compare treatment response in normal lung organoids and lung cancer<br /><br>tumoroids<br /><br>5. To develop biomarker(s) of tumor response to be able to select patients who<br /><br>will benefit from novel treatment strategies.<br /><br>6. To analyze (ct)DNA, RNA, proteins, metabolites, and microvesicles secreted<br /><br>by lung cancer cells in tumoroids-derived culture supernatants and<br /><br>corresponding patient-derived blood samples.<br /><br><br /><br></p><br>